Kira Gordon and Matt Majewski recently authored an article in MedTech Strategist discussing how hospital consolidation is increasing purchasing leverage through greater pricing transparency and that has substantiated a need for new pricing models in medtech. There are challenges associated with several emerging pricing models; regardless, manufacturers will need to develop innovative approaches to maximize opportunity while minimizing risk.
Beyond the single asset: The rise of combination and synergistic innovation in neurology drug development
Introduction Historically, drug development within the neurology space has been characterized by the search for individual therapies that can arrest complex...